Aachen (ots) - The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc., instead of Depomed, Inc., from 2018 onwards. In recent months, Depomed has been struggling to grow Nucynta®. Depomed executes its strategy to transform into a specialty pharmaceutical company with less focus ...
Lausanne (ots) - Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1347 for treatment of Biliary Tract Cancer affecting around ...
Lausanne, Switzerland (ots) - The clinical trial is in collaboration with the Merck-Pfizer Alliance Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the dosing of the first patient in a Phase Ib study of Debio ...
Zurich, Switzerland (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of "Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis", the results of the first ...
Atlanta, GA, USA and Lausanne, Switzerland (ots) - Triptodur(TM), (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injection. Arbor Pharmaceuticals, LLC, a U.S. based specialty ...
Lausanne (ots) - The 'JCA-Mauvernay Award 2017' is awarded to Doctors Yasuhiro Yamada and Hiroyoshi Nishikawa Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a Swiss-based global biopharmaceutical company, will be presenting the 'JCA-Mauvernay Award' on September 30 to Doctors Yasuhiro Yamada from the ...
Lausanne (ots) - Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics platform to develop novel therapeutics to combat drug-resistant gonorrhea. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...
Lausanne, Switzerland and Atlanta, GA (ots) - Triptodur (TM), (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty with once every six-month intramuscular injection (IM) dosing for children with CPP Approval brings new CPP treatment formulation ...
Québec, Canada (ots) - GenePOC announces the signing of an exclusive distribution agreement with Cardinal Health to become its commercial partner in the United States. GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is proud to announce that it has signed an exclusive distribution agreement with Cardinal ...
Craigavon, N.I., UK, Lausanne, Switzerland (ots) - Almac Discovery (www.almacgroup.com/discovery), a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA (Debiopharm - www.debiopharm.com), a Switzerland based specialty ...
Luxembourg, and Ness Ziona, Israel (ots) - - Cross reference: Picture is available at http://www.presseportal.de/pm/127019/3664051 - The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd., developer of the Universal Flu Vaccine candidate M-001, announced that they have entered into a EUR20 million loan ...
Lausanne (ots) - A total of 96 patients randomized in France and Switzerland. Results expected in Q1 2019. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the completion of enrollment in dose finding and ...
Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...
Lausanne, Switzerland (ots) - Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I ...
Lausanne, Switzerland and Waltham, Mass. (ots) - Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA ...
Aachen, Germany (ots) - - Grünenthal's new Innovation Hub in Greater Boston, U.S., shall accelerate easier access to and close collaboration with leading scientists and institutions - Grünenthal brings fully integrated R&D capabilities in pain to this community - there is no other company with so much focus on ...
Aachen (ots) - The Grünenthal Group announced today that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is Area Vice President, Southern and Western Europe, at AstraZeneca, based in the UK. He will join Grünenthal effective September 1, 2017. Mark Fladrich ...
Basel, Switzerland, Lausanne, Switzerland and Helsinki, Finland (ots) - Leading Big Data company developing platform with clinical and genomic data from 5 million subjects, to transform drug development and bring clinical benefits to patients. BC Platforms, a world leader in genomic data management solutions, today ...
Lausanne (ots) - Change in name reflects new strategy to invest in smart data, therapeutics and diagnostics Debiopharm Diagnostics SA, the strategic investment fund of Debiopharm Group(TM) (www.debiopharm.com), announced its new strategy and the change of name to Debiopharm Innovation Fund SA effective today. With the aim of speeding up innovations that radically ...
Aachen / Pisa (ots) - Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need - Neridronic acid is the first investigational medicine to receive Breakthrough Therapy ...
Aachen, Germany / Pittsburgh, PA, USA (ots) - - The acquisition supports Grünenthal's commercial and R&D strategy to drive innovation in pain. - Thar Pharmaceutical's lead compound, T121, complements Grünenthal's existing development pipeline and the goal of delivering innovative and effective treatments to ...
Melsungen/Johannesburg (ots) - On 30 June 2016, B. Braun Medical, the South African subsidiary of the German B. Braun Group, completed its acquisition of Dismed Pharmaceutical (Pty) Ltd and Dismed Criticare (Pty) Ltd, both out of business rescue. With over 600 employees in South Africa, B. Braun specialises in the ...
ITM Isotope Technologies Munich SE
Garching (ots) - The ITM Group announced today that the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) of the medicinal product EndolucinBeta, a radiopharmaceutical precursor. EndolucinBeta is not intended for direct use in patients but will be used for ...
Zug, Switzerland (ots) - Licence extension in the contract between AmVac and the Helmholtz Centre for the adjuvant Malp-2 offers sustainable potential for patients, attending physicians and for pharmaceutical and medical research. Milestone thanks to licence extension The licence for Malp-2 was successfully extended in November 2014. The adjuvant can now be used for the first time for all preventive and therapeutic ...
European Society for Medical Oncology (ESMO)
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
Eckert & Ziegler Strahlen und Medizintechnik AG
Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment and is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. The cooperation enfolds a brand-new ...
Montreal/Munich (ots) - Fund focuses on achieving human clinical proof-of-concept for early stage drug development projects, following a capital efficient investment approach in collaboration with Lilly TVM Capital Life Science, one of the leading life science venture capital firms in Canada, the United States and Europe, today announced the final closing of its latest ...
Aachen (ots) - EMBARGO: This information is for European healthcare professionals only. Not intended for UK audience. Low back pain is one of the most common chronic pain conditions. Studies have shown that up to 85% of people worldwide will suffer from back pain during their lives.(1) A high percentage of severe ...